Latest & greatest articles for ondansetron

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ondansetron or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ondansetron and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ondansetron

61. A systematic review of the antiemetic efficacy of prophylactic ondansetron compared with metoclopramide and with droperidol in adults

A systematic review of the antiemetic efficacy of prophylactic ondansetron compared with metoclopramide and with droperidol in adults A systematic review of the antiemetic efficacy of prophylactic ondansetron compared with metoclopramide and with droperidol in adults A systematic review of the antiemetic efficacy of prophylactic ondansetron compared with metoclopramide and with droperidol in adults Lim L, Dear K B, Heller R F Authors' objectives To compare prophylactic ondansetron (...) with metoclopramide and with droperidol in the prevention of post-operative vomiting (POV) in adults. Searching MEDLINE was searched from 1966, EMBASE from 1987, and Globe (a non-commercial database) from 1987, using the following index terms: 'ondansetron', 'metoclopramide', 'droperidol' and 'post-operative'. Studies published in any language were considered. Additional material was located by examining references from identified articles, review articles of the drugs studied, and conference abstracts

DARE.1999

62. Systematic review of ondansetron for the prevention and treatment of postoperative nausea and vomiting in adults

Systematic review of ondansetron for the prevention and treatment of postoperative nausea and vomiting in adults Systematic review of ondansetron for the prevention and treatment of postoperative nausea and vomiting in adults Systematic review of ondansetron for the prevention and treatment of postoperative nausea and vomiting in adults Cox F Authors' objectives To determine the efficacy and safety of ondansetron for the prevention and treatment of post-operative nausea and vomiting in adults (...) . Searching English language publications were sought in the following databases; EMBASE (1997); CINAHL (1990 to date); MEDLINE (1990 to date) and Cochrane Library (1998 Issue 1). The search used the combination (ondansetron and human and adults and (emesis or nausea or vomiting)) not (chemotherapy or cancer). Additional reports were identified from reference lists of retrieved reports and from review articles of PONV. The manufacturer of ondansetron supplied a review of the literature. A handsearch

DARE.1999

63. Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis

Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis Domino K B, Anderson E A, Polissar N L, Posner K L Authors (...) ' objectives To determine the relative efficacy and safety of the following drugs used prophylactically for the prevention of post-operative nausea and vomiting: ondansetron; droperidol; and metoclopramide. Searching A search was conducted of MEDLINE from January 1966 to May 1998 using the following terms: 'prevention', 'postoperative complications', 'nausea and vomiting', separately for 'ondansetron', 'droperidol' and 'metoclopramide'. A manual search was conducted of the table of contents in English

DARE.1999

64. Prophylactic ondansetron for postoperative emesis: meta-analysis of its effectiveness in patients with previous history of postoperative nausea and vomiting

Prophylactic ondansetron for postoperative emesis: meta-analysis of its effectiveness in patients with previous history of postoperative nausea and vomiting Prophylactic ondansetron for postoperative emesis: meta-analysis of its effectiveness in patients with previous history of postoperative nausea and vomiting Prophylactic ondansetron for postoperative emesis: meta-analysis of its effectiveness in patients with previous history of postoperative nausea and vomiting Figueredo E, Canosa L (...) Authors' objectives To assess the postoperative antiemetic efficacy of ondansetron in patients with and without antecedents of post-operative nausea and vomiting (PH-PONV). Searching The authors searched the electronic databases of MEDLINE and EMBASE (January 1990 to July 1998) using the search terms: 'ondansetron', 'anaesthesia/anesthesia' and 'vomiting'. Additional studies were identified from the reference sections of retrieved studies and from two previous meta-analyses. There were no language

DARE.1999

65. The search for cost-effective prevention of postoperative nausea and vomiting in the child undergoing reconstructive burn surgery: ondansetron versus dimenhydrinate

The search for cost-effective prevention of postoperative nausea and vomiting in the child undergoing reconstructive burn surgery: ondansetron versus dimenhydrinate The search for cost-effective prevention of postoperative nausea and vomiting in the child undergoing reconstructive burn surgery: ondansetron versus dimenhydrinate The search for cost-effective prevention of postoperative nausea and vomiting in the child undergoing reconstructive burn surgery: ondansetron versus dimenhydrinate (...) McCall J E, Stubbs K, Saylors S, Pohlman S, Ivers B, Smith S, Fischer C G, Kopcha R, Warden G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of ondansetron versus dimenhydrinate in the prevention of postoperative nausea

NHS Economic Evaluation Database.1999

66. Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer

Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer Lachaine J, Laurier C, Langleben A, Vaillant L (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Ondansetron- and metoclopramide-based antiemetic regimens were compared in breast cancer patients receiving cyclophosphamide chemotherapy (moderately emetogenic). The protocol and dose

NHS Economic Evaluation Database.1999

67. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy.

Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. 10437877 1999 08 12 1999 08 12 2015 06 16 0140-6736 354 9176 1999 Jul 31 Lancet (London, England) Lancet Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. 397 A woman with chronic hepatitis C and profound fatigue became symptomfree when treated long-term with ondansetron 4 mg twice daily. Altered central serotoninergic neurotransmission may (...) contribute to fatigue complicating chronic liver disease. Jones E A EA eng Case Reports Clinical Trial Letter Randomized Controlled Trial England Lancet 2985213R 0140-6736 0 Serotonin Antagonists 4AF302ESOS Ondansetron AIM IM Adult Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Fatigue drug therapy Female Hepatitis C, Chronic drug therapy Humans Liver Function Tests Ondansetron administration & dosage adverse effects Serotonin Antagonists administration & dosage adverse

Lancet1999

68. Ondansetron in the prophylaxis of postoperative vomiting: a meta-analysis

Ondansetron in the prophylaxis of postoperative vomiting: a meta-analysis Ondansetron in the prophylaxis of postoperative vomiting: a meta-analysis Ondansetron in the prophylaxis of postoperative vomiting: a meta-analysis Figueredo E D, Canosa L G Authors' objectives To assess the effectiveness of prophylactic ondansetron for the prevention of vomiting, and on the incidence of headache when used post-operatively. Searching MEDLINE was searched from January 1990 to July 1997 using the keywords (...) 'vomiting', 'ondansetron', and 'surgery' and/or 'anasthesia/anaesthesia'. Studies published in any language were considered. Abstracts and unpublished studies were excluded from the search. A scan of the retrieved articles revealed no additional studies. Study selection Study designs of evaluations included in the review The included trials were prospectively randomised and placebo-controlled, divided into early (up to 8 hours post-operative) and late (up to 24 hours post-operative) evaluation. Specific

DARE.1998

69. The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting

The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting Tang J, Wang B G (...) , White P F, Watcha M F, Qi J H, Wender R H Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology studied was ondansetron in various doses and stages of administration in the prevention and treatment of postoperative

NHS Economic Evaluation Database.1998

70. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials

Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review (...) of randomized placebo-controlled trials Tramer M R, Reynolds J M, Moore R A, McQuay H J Authors' objectives To assess the efficacy of ondansetron, compared with placebo or no treatment, for the prevention of post-operative nausea and vomiting (PONV); to test dose-response evidence; to identify the optimal dose for oral and intravenous routes; to compare anti-nausea with anti-vomiting efficacies; and to investigate the potential of ondansetron for toxic effects in the surgical setting. Searching MEDLINE

DARE.1997

71. A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting

A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting Tramer M R, Moore R A, Reynolds D J, McQuay H J Authors' objectives To assess the evidence for a dose-response with ondansetron for the treatment of post-operative (...) nausea and vomiting, and to establish whether differences in efficacy between doses are of clinical relevance. Searching MEDLINE was searched from 1991 to January 1996 for publications in any language, using the search terms 'ondansetron' and 'human' combined with 'emesis', 'nausea' or 'vomiting', but not 'chemotherapy' or 'cancer'. Additional material was obtained by examining reference lists of retrieved reports, review articles from anaesthesia journals and a manufacturer's database of published

DARE.1997

72. Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy

Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy Ondansetron versus (...) on the reliability of the study and the conclusions drawn. Health technology The use of ondansetron (a 5HT3 receptor antagonist) in the prevention of nausea and vomiting following single-fraction radiotherapy. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients over the age of 18 who were receiving palliative single-fraction radiotherapy. Setting Hospital setting. The study was carried out at the Christie Hospital, Manchester, UK. Dates to which data relate

NHS Economic Evaluation Database.1997

73. Vomiting after strabismus surgery in children: ondansetron vs propofol

Vomiting after strabismus surgery in children: ondansetron vs propofol Vomiting after strabismus surgery in children: ondansetron vs propofol Vomiting after strabismus surgery in children: ondansetron vs propofol Splinter W M, Rhine E J, Roberts D J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Two different anaesthetic regimens, intended to reduce the rate of post-operative emesis, namely inhaled halothane combined with oral ondansetron, or propofol plus intra venous lidocaine. Type of intervention Treatment; Anaesthesia. Economic study type Cost-effectiveness analysis. Study population The study population consisted of children between the ages of 2 and 14 undergoing elective strabismus surgery. Setting The study setting

NHS Economic Evaluation Database.1997

74. A pilot study to evaluate the cost-effectiveness of ondansetron and granisetron in fractionated total body irradiation

A pilot study to evaluate the cost-effectiveness of ondansetron and granisetron in fractionated total body irradiation A pilot study to evaluate the cost-effectiveness of ondansetron and granisetron in fractionated total body irradiation A pilot study to evaluate the cost-effectiveness of ondansetron and granisetron in fractionated total body irradiation Gibbs S J, Cassoni A M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Intravenous granisetron 3 mg (in a single dose), with a second dose on failure versus twice-daily oral ondansetron 8 mg given 30 minutes before each fraction in order to prevent radiation-induced emesis during fractionated total body irradiation in patients undergoing total body irradiation prior

NHS Economic Evaluation Database.1996

75. A comparison of costs and efficacy of ondansetron and droperidol as prophylactic antiemetic therapy for elective outpatient gynecologic procedures

A comparison of costs and efficacy of ondansetron and droperidol as prophylactic antiemetic therapy for elective outpatient gynecologic procedures A comparison of costs and efficacy of ondansetron and droperidol as prophylactic antiemetic therapy for elective outpatient gynecologic procedures A comparison of costs and efficacy of ondansetron and droperidol as prophylactic antiemetic therapy for elective outpatient gynecologic procedures Tang J, Watcha M F, White P F Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of ondansetron or droperidol given prior to surgery to prevent post-operative nausea and vomiting (PONV). Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study

NHS Economic Evaluation Database.1996

76. Ondansetron

Ondansetron Ondansetron Ondansetron University HealthSystem Consortium Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation University HealthSystem Consortium. Ondansetron. Oak Brook, Illinois: University Healthsystem Consortium 1993: 95 Authors' objectives Includes UHC ondansetron-prescribing guidelines developed by a UHC expert panel, as well as the results of UHC (...) member surveys that reviewed ondansetron use, drug use evaluations, and cost-containment efforts. A literature review, an annotated bibliography, and a separate drug monograph round out this assessment. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Antiemetics /therapeutic use Language Published English Country of organisation United States Address for correspondence University HealthSystem Consortium, 2001 Spring Rd., Suite 700, Oak Brook, IL 60523 USA. Tel: 630-954-1700

Health Technology Assessment (HTA) Database.1993

77. The real costs of emesis: an economic analysis of ondansetron vs metoclopramide in controlling emesis in patients receiving chemotherapy for cancer

The real costs of emesis: an economic analysis of ondansetron vs metoclopramide in controlling emesis in patients receiving chemotherapy for cancer The real costs of emesis: an economic analysis of ondansetron vs metoclopramide in controlling emesis in patients receiving chemotherapy for cancer The real costs of emesis: an economic analysis of ondansetron vs metoclopramide in controlling emesis in patients receiving chemotherapy for cancer Cunningham D, Gore M, Davidson N, Miocevich M (...) , Manchanda M, Wells N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two medications, ondansetron and metoclopramide, used for controlling emesis in patients receiving chemotherapy for cancer. Type of intervention Treatment. Economic

NHS Economic Evaluation Database.1993

78. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.

Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. 8455665 1993 04 19 1993 04 19 2013 11 21 0028-4793 328 15 1993 Apr 15 The New England journal of medicine N. Engl. J. Med. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. 1081-4 Although ondansetron was found (...) to be effective as an antiemetic in numerous clinical trials of highly emetogenic combination-chemotherapy regimens that included cisplatin, its role in milder emetogenic regimens has not been fully defined. To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil. A total of 165

NEJM1993

79. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.

Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. 8455664 1993 04 19 1993 04 19 2013 11 21 0028-4793 328 15 1993 Apr 15 The New England journal of medicine N. Engl. J. Med. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. 1076-80 The serotonin (5-hydroxytryptamine3) antagonists have improved the treatment of acute chemotherapy-induced nausea and vomiting (...) , but their ability to prevent delayed nausea and vomiting seems less pronounced. The results of a preliminary open trial suggested that the addition of a selective dopamine D2 antagonist could improve the antiemetic efficacy of the serotonin antagonists. In a randomized, double-blind, crossover trial, we compared oral treatment with ondansetron (8 mg twice a day) and the dopamine D2 antagonist metopimazine (30 mg four times a day) with treatment with ondansetron alone for three days in 30 patients who had

NEJM1993

80. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.

Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research. 1352024 1992 07 30 1992 07 30 2015 06 16 0140-6736 340 8811 1992 Jul 11 Lancet (London, England) Lancet Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research. 96-9 Ondansetron, a selective serotonin-receptor antagonist (...) , is an effective antiemetic for patients receiving high-dose cisplatin chemotherapy. However, no comparison has been made between a combination of a serotonin antagonist and dexamethasone, which also has antiemetic properties, with currently available antiemetic regimens. 289 consecutive cancer patients receiving cisplatin chemotherapy (much greater than 50 mg/m2) were randomised to receive one of the following intravenous antiemetic regimens: ondansetron 0.15 mg/kg, before and after cisplatin, + dexamethasone

Lancet1992